{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:46:10Z","timestamp":1791359170051,"version":"4.3.1"},"reference-count":84,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>There is an increasing number of studies using real-world data to examine outcomes of drugs in clinical practice. Therefore, it is crucial to carefully evaluate their quality and findings, extract valuable insights, acknowledge their limitations and identify gaps to advance further their use in decision-making. Here we provide an overview of the opportunities offered throughout drug lifecycle, and challenges presented by real-world evidence (RWE) studies. We also highlight the importance of the culture of transparency, along with the development of good practices for reporting RWE studies. In addition, we review common biases and other methodological aspects that can undermine the potential insights a real-world oncology study can provide. We briefly illustrate some questions that RWE studies address that can help us guide clinical decisions. Several possible future directions expected to contribute for RWE improving cancer patients' outcomes emerge, from prospective data collection initiatives to normalization of biomarker data integration or collaborative data sharing platforms.<\/jats:p>","DOI":"10.57264\/cer-2025-0186","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:03:22Z","timestamp":1777039402000},"source":"Crossref","is-referenced-by-count":2,"title":["Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Bermejo","sequence":"first","affiliation":[{"name":"Medical Oncology, Hospital Cl\u00ednico Universitario de Valencia; Valencia, Spain"},{"name":"Biomedical Research Institute INCLIVA, Valencia, Spain"},{"name":"Medicine Department, Universidad de Valencia, Valencia, Spain"},{"name":"Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-318X","authenticated-orcid":false,"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[{"name":"Oncology Data Science, Vall d\u00b4Hebron Institute of Oncology, Barcelona, Spain"},{"name":"Oncocl\u00ednicas &amp; CO, S\u00e3o Paulo, Brazil"},{"name":"University of Vic \u2013 Central University of Catalonia, Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-8307","authenticated-orcid":false,"given":"Meritxell","family":"Bellet","sequence":"additional","affiliation":[{"name":"Oncology Department, Breast Cancer Unit, Vall d'Hebron University Hospital, Barcelona, Spain"},{"name":"Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6893-6628","authenticated-orcid":false,"given":"Susana de","family":"la Cruz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Navarra University Hospital - IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-5736","authenticated-orcid":false,"given":"Elena","family":"Galve-Calvo","sequence":"additional","affiliation":[{"name":"Oncologia M\u00e9dica. Hospital Universitario Basurto (OSI Bilbao-Basurto); Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-2626","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Obadia","sequence":"additional","affiliation":[{"name":"Oncology Department, Breast Cancer Unit, Catalan Institute of Oncology (ICO) Hospitalet de Llobregat, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), Barcelona University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-320X","authenticated-orcid":false,"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, La Fe Health Research Institute (IISLaFe), La Fe University Hospital, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-4152","authenticated-orcid":false,"given":"Roc\u00edo","family":"Ramos-Medina","sequence":"additional","affiliation":[{"name":"Medical Department, Pfizer Oncology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6472-5359","authenticated-orcid":false,"given":"M\u00f3nica","family":"Cuenca","sequence":"additional","affiliation":[{"name":"Medical Department, Pfizer Oncology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-0687","authenticated-orcid":false,"given":"Fernando","family":"Moreno","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"S925","DOI":"10.1016\/j.annonc.2023.09.2643","article-title":"1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: a collaborative work from ESMO real-world data and digital health working group","volume":"34","author":"Pellat A","year":"2023","unstructured":"Pellat A, Grinda T, Prelaj A 1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: a collaborative work from ESMO real-world data and digital health working group. Ann. Oncol. 34, S925 (2023).","journal-title":"Ann. Oncol."},{"issue":"5","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth CM","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat. Rev. Clin. Oncol. 16(5), 312\u2013325 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"100424","DOI":"10.1016\/j.jcpo.2023.100424","article-title":"The role of real-world data and evidence in oncology medicines approved in EU in 2018\u20132019","volume":"36","author":"Eskola SM","year":"2023","unstructured":"Eskola SM, Leufkens HGM, Bate A, Louise M, Bruin D, Gardarsdottir H. The role of real-world data and evidence in oncology medicines approved in EU in 2018\u20132019. J. Cancer Policy 36, 100424 (2023).","journal-title":"J. Cancer Policy"},{"issue":"1","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","article-title":"Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020","volume":"28","author":"Arondekar B","year":"2022","unstructured":"Arondekar B, Duh MS, Bhak RH Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020. Clin. Cancer Res. 28(1), 27\u201335 (2022).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a canadian review and perspective","volume":"27","author":"Azoulay L","year":"2022","unstructured":"Azoulay L. Rationale, strengths, and limitations of real-world evidence in oncology: a canadian review and perspective. Oncologist 27, e731\u2013e738 (2022).","journal-title":"Oncologist"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030165"},{"issue":"11","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin S","year":"2017","unstructured":"Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J. Natl Cancer Inst. 109(11), djx187 (2017).","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.3747\/co.26.5625","article-title":"Role of real-world evidence in informing cancer care: lessons from colorectal cancer","volume":"26","author":"Batra A","year":"2019","unstructured":"Batra A, Cheung WY. Role of real-world evidence in informing cancer care: lessons from colorectal cancer. Curr. Oncol. 26(Suppl. 1), S53\u2013S56 (2019).","journal-title":"Curr. Oncol."},{"issue":"1","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais S","year":"2022","unstructured":"Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin. Pharmacol. Ther. 111(1), 77\u201389 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_6_12_2","unstructured":"European Medicines Agency. Final report on the adaptive pathways pilot. https:\/\/www.ema.europa.eu\/en\/documents\/report\/final-report-adaptive-pathways-pilot_en.pdf"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1658"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.001"},{"key":"e_1_3_6_15_2","unstructured":"Food and Drug Administration. Framework for FDA\u2019s real-world evidence program. https:\/\/www.fda.gov\/media\/120060\/download"},{"issue":"10","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"e1912869","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence","volume":"2","author":"Bartlett VL","year":"2019","unstructured":"Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open 2(10), e1912869. (2019).","journal-title":"JAMA Netw. Open"},{"key":"e_1_3_6_17_2","unstructured":"Mercon K Mahendraratnam N Eckert J A roadmap for developing study endpoints in real-world settings. (2020). Duke. Margolis Institute for Health Policy. https:\/\/healthpolicy.duke.edu\/publications\/roadmap-developing-study-endpoints-real-world-settings"},{"issue":"1","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","article-title":"Bridging the gap between RCTs and RWE through endpoint selection","volume":"55","author":"LoCasale RJ","year":"2021","unstructured":"LoCasale RJ, Pashos CL, Gutierrez B Bridging the gap between RCTs and RWE through endpoint selection. Ther. Innov. Regul. Sci. 55(1), 90\u201396 (2021).","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"2","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clinthera.2021.12.010","article-title":"Real-world data in the postapproval setting as applied by the EMA and the US FDA","volume":"44","author":"Mofid S","year":"2022","unstructured":"Mofid S, Bolislis WR, K\u00fchler TC. Real-world data in the postapproval setting as applied by the EMA and the US FDA. Clin. Ther. 44(2), 306\u2013322 (2022).","journal-title":"Clin. Ther."},{"issue":"5","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinthera.2020.03.006","article-title":"Review use of real-world data for new drug applications and line extensions","volume":"42","author":"Bolislis WR","year":"2020","unstructured":"Bolislis WR, Fay M, K\u00fchler TC. Review use of real-world data for new drug applications and line extensions. Clin. Ther. 42(5), 926\u2013938 (2020).","journal-title":"Clin. Ther."},{"issue":"1","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cpt.2454","article-title":"Real-world data of palbociclib in combination with endocrine therapy for the treatment of metastatic breast cancer in men","volume":"111","author":"Kraus A","year":"2022","unstructured":"Kraus A, Yu-Kite M, Mardekian J Real-world data of palbociclib in combination with endocrine therapy for the treatment of metastatic breast cancer in men. Clin. Pharmacol. Ther. 111(1), 302\u2013309 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam S","year":"2020","unstructured":"Wedam S, Fashoyin-aje L, Bloomquist E FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin. Cancer Res. 26, 1208\u20131212 (2020).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.breast.2021.12.015","article-title":"The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making","volume":"61","author":"Cottu P","year":"2022","unstructured":"Cottu P, Ramsey SD, Sol\u00e0-Morales O, Spears PA, Taylor L. The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making. Breast 61, 118\u2013122 (2022).","journal-title":"Breast"},{"issue":"1","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2462","article-title":"Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019","volume":"111","author":"Eskola SM","year":"2022","unstructured":"Eskola SM, Gerardus H, Leufkens M, Bate A, De Bruin ML, Gardarsdottir H. Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019. Clin. Pharmacol. Ther. 111(1), 310\u2013320 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.currproblcancer.2021.100769","article-title":"Using real world data to support regulatory approval of drugs in rare diseases: a review of opportunities, limitations & a case example","volume":"45","author":"Gross AM","year":"2021","unstructured":"Gross AM. Using real world data to support regulatory approval of drugs in rare diseases: a review of opportunities, limitations & a case example. Curr. Probl. Cancer 45(4), 100769 (2021).","journal-title":"Curr. Probl. Cancer"},{"issue":"4","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s43441-023-00528-y","article-title":"Statistical considerations on the use of RWD\/RWE for oncology drug approvals: overview and lessons learned in oncology drug development","volume":"57","author":"Ro SK","year":"2023","unstructured":"Ro SK, Zhang W, Jiang Q Statistical considerations on the use of RWD\/RWE for oncology drug approvals: overview and lessons learned in oncology drug development. Ther. Innov. Regul. Sci. 57(4), 899\u2013910 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"e_1_3_6_27_2","first-page":"e2300261","article-title":"The bar is high: evaluating fit-for-use oncology real-world data for regulatory decision making","volume":"8","author":"Lerro CC","year":"2024","unstructured":"Lerro CC, Bradley MC, Forshee RA, Rivera DR. The bar is high: evaluating fit-for-use oncology real-world data for regulatory decision making. JCO Clin. Cancer Inf. 8, e2300261 (2024).","journal-title":"JCO Clin. Cancer Inf."},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"e2300046","DOI":"10.1200\/CCI.23.00046","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions","volume":"8","author":"Castellanos EH","year":"2024","unstructured":"Castellanos EH, Wittmershaus BK, Chandwani S. Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions. JCO Clin. Cancer Inform. 8, e2300046 (2024).","journal-title":"JCO Clin. Cancer Inform."},{"issue":"5","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss S","year":"2006","unstructured":"Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol. Drug Saf. 15(5), 291\u2013303 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2288-13-92","article-title":"A tutorial on sensitivity analyses in clinical trials: the what, why, when and how","volume":"13","author":"Thabane L","year":"2013","unstructured":"Thabane L, Mbuagbaw L, Zhang S A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med. Res. Methodol. 13, 92 (2013).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_6_31_2","volume-title":"Secondary Analysis of Electronic Health Records [Internet]","author":"Salciccioli JD","year":"2016","unstructured":"Salciccioli JD, Crutain Y, Komorowski M, Marshall DC. Sensitivity analysis and model validation. 2016 Sep 10. In: MIT Critical Data. Secondary Analysis of Electronic Health Records [Internet]. Springer, Cham (CH) (2016). Chapter 17."},{"issue":"2","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/curroncol30020151","article-title":"Selection bias in real-world data studies used to support health technology assessments: a case study in metastatic cancer","volume":"30","author":"Jarada TN","year":"2023","unstructured":"Jarada TN, Sullivan DEO, Brenner DR, Cheung WY, Boyne DJ. Selection bias in real-world data studies used to support health technology assessments: a case study in metastatic cancer. Curr. Oncol. 30(2), 1945\u20131953 (2023).","journal-title":"Curr. Oncol."},{"issue":"9","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pds.5083","article-title":"Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa S","year":"2020","unstructured":"Suissa S, Dell'Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol. Drug Saf. 29(9), 1101\u20131110 (2020).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","article-title":"Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative","volume":"23","author":"Orsini LS","year":"2020","unstructured":"Orsini LS, Berger M, Crown W Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Value Health 23(9), 1128\u20131136 (2020).","journal-title":"Value Health"},{"key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/cancers14133063","article-title":"Considerations for the use of machine learning extracted real-world data to support evidence generation: a research-centric evaluation framework","volume":"14","author":"Estevez M","year":"2022","unstructured":"Estevez M, Benedum CM, Jiang C Considerations for the use of machine learning extracted real-world data to support evidence generation: a research-centric evaluation framework. Cancers (Basel) 14, 3063 (2022).","journal-title":"Cancers (Basel)"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061853"},{"key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/BCTT.S162841","article-title":"Progression-free survival\/time to progression as a potential surrogate for overall survival in HR+, HER2\u2013 metastatic breast cancer","volume":"10","author":"Forsythe A","year":"2018","unstructured":"Forsythe A, Chandiwana D, Barth J, Baeck J, Tremblay G. Progression-free survival\/time to progression as a potential surrogate for overall survival in HR+, HER2\u2013 metastatic breast cancer. Breast Cancer - Targets Ther. 10, 69\u201378 (2018).","journal-title":"Breast Cancer - Targets Ther."},{"key":"e_1_3_6_38_2","article-title":"Assessment of select HER2-negative mBC agents as a proxy to understand HTA-body uncertainties for HER2-low mBC agents in EU4 and England","author":"Anastasaki E","year":"2021","unstructured":"Anastasaki E, Harding T, Seddik A, Oddsdottir JSP. Assessment of select HER2-negative mBC agents as a proxy to understand HTA-body uncertainties for HER2-low mBC agents in EU4 and England. Poster presented at: ISPOR EUROPE (2021).","journal-title":"ISPOR EUROPE"},{"issue":"1","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele A","year":"2021","unstructured":"DeMichele A, Cristofanilli M, Brufsky A Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 23(1), 37 (2021).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"Rugo HS","year":"2022","unstructured":"Rugo HS, Brufsky A, Liu X Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer. NPJ Breast Cancer 8(1), 114 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"e_1_3_6_41_2","article-title":"Criterios RECIST 1.1: actualizaci\u00f3n y an\u00e1lisis","author":"Macho EA","year":"2022","unstructured":"Macho EA, Fern\u00e1ndez AM, Parente AS Criterios RECIST 1.1: actualizaci\u00f3n y an\u00e1lisis. Presented at: 36th meeting of the Spanish Society of Medical Radiology \u2013 (SERAM). (2022). https:\/\/piper.espacio-seram.com\/index.php\/seram\/article\/view\/8629\/7095","journal-title":"36th meeting of the Spanish Society of Medical Radiology \u2013 (SERAM)"},{"issue":"5","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","article-title":"Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice","volume":"16","author":"Brufsky A","year":"2021","unstructured":"Brufsky A, Liu X, Li B, Mcroy L, Layman RM. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol. 16(5), 601\u2013611 (2021).","journal-title":"Target Oncol."},{"key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanwpc.2022.100624","article-title":"The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges","volume":"31","author":"Huang H","year":"2023","unstructured":"Huang H, Tang Y, Yu Y The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges. Lancet Reg. Heal. - West. Pacific. 31, 100624 (2023).","journal-title":"Lancet Reg. Heal. - West. Pacific."},{"issue":"1","key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies","volume":"111","author":"Rivera DR","year":"2022","unstructured":"Rivera DR, Henk HJ, Garrett-Mayer E The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies. Clin. Pharmacol. Ther. 111(1), 283\u2013292 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"23","key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2217\/fon-2022-0616","article-title":"Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors","volume":"19","author":"Agapow P","year":"2023","unstructured":"Agapow P, Mulla R, Markuzon N, Ottesen LH, Meulendijks D. Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors. Future Oncol. 19(23), 1627\u20131639 (2023).","journal-title":"Future Oncol."},{"issue":"1","key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"e000783","DOI":"10.1136\/bmjonc-2025-000783","article-title":"Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)","volume":"4","author":"Puccini A","year":"2025","unstructured":"Puccini A, Viscardi G, Ciani O Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM). BMJ Oncol. 4(1), e000783 (2025).","journal-title":"BMJ Oncol."},{"issue":"1","key":"e_1_3_6_47_2","doi-asserted-by":"crossref","first-page":"e25792","DOI":"10.2196\/25792","article-title":"Integrating quality of life in the care pathway of cancer patients undergoing immunotherapy treatment: descriptive, cross-sectional survey of an online patient community's experiences and expectations","volume":"24","author":"Wilczynski O","year":"2022","unstructured":"Wilczynski O, Boisbouvier A, Radoszycki L, Cott\u00e9 F-E, Gaudin A-F, Lemasson H. Integrating quality of life in the care pathway of cancer patients undergoing immunotherapy treatment: descriptive, cross-sectional survey of an online patient community's experiences and expectations. J. Med. Internet Res. 24(1), e25792 (2022).","journal-title":"J. Med. Internet Res."},{"issue":"10","key":"e_1_3_6_48_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/d41573-019-00088-7","article-title":"Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes","volume":"18","author":"Calvert MJ","year":"2019","unstructured":"Calvert MJ, O'Connor DJ, Basch EM. Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes. Nat. Rev. Drug Discov. 18(10), 731\u2013732 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"e2424793","DOI":"10.1001\/jamanetworkopen.2024.24793","article-title":"Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis","volume":"7","author":"Balitsky AK","year":"2024","unstructured":"Balitsky AK, Rayner D, Britto J Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis. JAMA Netw. Open 7(8), e2424793 (2024).","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jamaoncol.2025.3153","article-title":"Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis","volume":"11","author":"Huang RS","year":"2025","unstructured":"Huang RS, Chen D, Benour A Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis. JAMA Oncol. 11(11), 1303\u20131312 (2025).","journal-title":"JAMA Oncol."},{"issue":"9","key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"e20157","DOI":"10.1016\/j.heliyon.2023.e20157","article-title":"Paving the way for patient centricity in real-world evidence (RWE): qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation","volume":"9","author":"Maruszczyk K","year":"2023","unstructured":"Maruszczyk K, McMullan C, Aiyegbusi OL Paving the way for patient centricity in real-world evidence (RWE): qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation. Heliyon 9(9), e20157 (2023).","journal-title":"Heliyon"},{"issue":"8","key":"e_1_3_6_52_2","doi-asserted-by":"crossref","first-page":"e2424748","DOI":"10.1001\/jamanetworkopen.2024.24748","article-title":"Patient-Reported Outcome Measures Help Patients With Cancer","volume":"7","author":"Hassett MJ","year":"2024","unstructured":"Hassett MJ, Cronin C. Patient-Reported Outcome Measures Help Patients With Cancer. JAMA Netw. Open 7(8), e2424748 (2024).","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"e_1_3_6_53_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jmrs.421","article-title":"A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care","volume":"68","author":"Nguyen H","year":"2021","unstructured":"Nguyen H, Butow P, Dhillon H, Sundaresan P. A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care. J. Med. Radiat. Sci. 68(2), 186\u2013195 (2021).","journal-title":"J. Med. Radiat. Sci."},{"issue":"1","key":"e_1_3_6_54_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-024-00710-w","article-title":"Evaluating comprehensibility of 157 patient-reported outcome measures (PROMs) in the Nationwide Dutch Outcome-based healthcare program: more attention for comprehensibility of PROMs is needed","volume":"18","author":"Tuinenburg A","year":"2025","unstructured":"Tuinenburg A, Determann D, Quik EH Evaluating comprehensibility of 157 patient-reported outcome measures (PROMs) in the Nationwide Dutch Outcome-based healthcare program: more attention for comprehensibility of PROMs is needed. Patient 18(1), 65\u201376 (2025).","journal-title":"Patient"},{"issue":"11","key":"e_1_3_6_55_2","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.mayocp.2019.04.005","article-title":"Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology","volume":"94","author":"Warsame R","year":"2019","unstructured":"Warsame R, D'Souza A. Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology. Mayo Clin. Proc. 94(11), 2291\u20132301 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad207"},{"key":"e_1_3_6_57_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/PROM.S468623","article-title":"Development and content validation of the patient's qualitative assessment of treatment - real-world (PQAT-RW): an instrument to evaluate benefits and disadvantages of treatments in real-world settings","volume":"15","author":"Roborel de Climens A","year":"2024","unstructured":"Roborel de Climens A, Findley A, Bury DP, Brady KJS, Reaney M, Gater A. Development and content validation of the patient's qualitative assessment of treatment - real-world (PQAT-RW): an instrument to evaluate benefits and disadvantages of treatments in real-world settings. Patient Relat. Outcome Meas. 15, 255\u2013269 (2024).","journal-title":"Patient Relat. Outcome Meas."},{"issue":"4","key":"e_1_3_6_58_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00404-024-07886-4","article-title":"Lower extremity lymphedema in patients with gynecologic cancer: validation of the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) in German language and investigation of lymphedema real-world treatment","volume":"311","author":"Meyer H","year":"2025","unstructured":"Meyer H, Hinz A, Weisgerber C Lower extremity lymphedema in patients with gynecologic cancer: validation of the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) in German language and investigation of lymphedema real-world treatment. Arch. Gynecol. Obstet. 311(4), 1151\u20131162 (2025).","journal-title":"Arch. Gynecol. Obstet."},{"issue":"11","key":"e_1_3_6_59_2","doi-asserted-by":"crossref","first-page":"e70324","DOI":"10.1002\/pon.70324","article-title":"Establishing the ecological validity of cognitive patient reported outcome measures in breast cancer survivors: a prospective cohort study","volume":"34","author":"Henneghan AM","year":"2025","unstructured":"Henneghan AM, Franco-Rocha OY, Van Dyk KM, Paolillo EW, Haywood D, Moore RC. Establishing the ecological validity of cognitive patient reported outcome measures in breast cancer survivors: a prospective cohort study. Psychooncology 34(11), e70324 (2025).","journal-title":"Psychooncology"},{"issue":"11","key":"e_1_3_6_60_2","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang XS","year":"2021","unstructured":"Wang XS, Srour SA, Whisenant M Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther. 27(11), 930.e1\u2013930.e10 (2021).","journal-title":"Transplant Cell Ther."},{"issue":"4","key":"e_1_3_6_61_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s11764-021-01160-1","article-title":"Phase III study of the European organization for research and treatment of cancer quality of life cancer survivorship core questionnaire","volume":"17","author":"van Leeuwen M","year":"2023","unstructured":"van Leeuwen M, Kieffer JM, Young TE Phase III study of the European organization for research and treatment of cancer quality of life cancer survivorship core questionnaire. J. Cancer Surviv. 17(4), 1111\u20131130 (2023).","journal-title":"J. Cancer Surviv."},{"issue":"10","key":"e_1_3_6_62_2","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers13102308","article-title":"Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach","volume":"13","author":"Clarijs ME","year":"2021","unstructured":"Clarijs ME, Thurell J, K\u00fchn F Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach. Cancers (Basel) 13(10), 2308 (2021).","journal-title":"Cancers (Basel)"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4297"},{"key":"e_1_3_6_64_2","unstructured":"UNESCO. UNESCO recommendation on open science. (2021). https:\/\/unesdoc.unesco.org\/ark:\/48223\/pf0000379949"},{"key":"e_1_3_6_65_2","unstructured":"ISPOR. Real-World Evidence Registry (2023). https:\/\/www.ispor.org\/strategic-initiatives\/real-world-evidence\/real-world-evidence-registry"},{"key":"e_1_3_6_66_2","unstructured":"European Medicines Agency. HMA-EMA catalogues of real-world data sources and studies. https:\/\/catalogues.ema.europa.eu\/"},{"issue":"4","key":"e_1_3_6_67_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11864-024-01186-4","article-title":"Harnessing the potential of real - world evidence in the treatment of colorectal cancer: where do we stand?","volume":"25","author":"van Nassau SCMW","year":"2024","unstructured":"van Nassau SCMW, Bol GM, van der Baan FH Harnessing the potential of real - world evidence in the treatment of colorectal cancer: where do we stand? Curr. Treat. Options Oncol. 25(4), 405\u2013426 (2024).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"20","key":"e_1_3_6_68_2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner NC","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379(20), 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_6_69_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon DJ","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS Overall survival with palbociclib plus letrozole in advanced breast cancer. J. Clin. Oncol. 42(9), 994\u20131000 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"e_1_3_6_70_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/oncolo\/oyae273","article-title":"Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in metastatic breast cancer patients with cardiovascular diseases","volume":"29","author":"Brufsky A","year":"2024","unstructured":"Brufsky A, Liu X, Li B Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in metastatic breast cancer patients with cardiovascular diseases. Oncologist 29(12), 1032\u20131043 (2024).","journal-title":"Oncologist"},{"issue":"1","key":"e_1_3_6_71_2","doi-asserted-by":"crossref","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo HS","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open 10(1), 104103 (2025).","journal-title":"ESMO Open"},{"issue":"10","key":"e_1_3_6_72_2","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela M","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M\u00c1 Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int. J. Mol. Sci. 24(10), 8488 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"e_1_3_6_73_2","doi-asserted-by":"crossref","first-page":"1203684","DOI":"10.3389\/fonc.2023.1203684","article-title":"The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study","volume":"13","author":"Al-ziftawi NH","year":"2023","unstructured":"Al-ziftawi NH, Elazzazy S, Bbujassoum S, Izham M, Ibrahim M. The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study. Front. Oncol. 13, 1203684 (2023).","journal-title":"Front. Oncol."},{"issue":"21","key":"e_1_3_6_74_2","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.3390\/cancers15215164","article-title":"Clinical impact of CDK4\/6 Inhibitors in de novo or PR- or very elderly post-menopausal ER+\/HER2- advanced breast cancers","volume":"15","author":"Tang H","year":"2023","unstructured":"Tang H, Yeo D, De Souza K Clinical impact of CDK4\/6 Inhibitors in de novo or PR- or very elderly post-menopausal ER+\/HER2- advanced breast cancers. Cancers (Basel) 15(21), 5164 (2023).","journal-title":"Cancers (Basel)"},{"issue":"10","key":"e_1_3_6_75_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/fon-2022-1287","article-title":"Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"19","author":"Kahraman S","year":"2023","unstructured":"Kahraman S, Erul E, Seyyar M Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer. Future Oncol. 19(10), 727\u2013736 (2023).","journal-title":"Future Oncol."},{"issue":"8","key":"e_1_3_6_76_2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/10781552231163121","article-title":"CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset","volume":"29","author":"Buller W","year":"2023","unstructured":"Buller W, Pallan L, Chu T, Khoja L. CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset. J. Oncol. Pharm. Pract. 29(8), 1825\u20131835 (2023).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"e_1_3_6_77_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2020.7662","article-title":"Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience","author":"Wander SA","year":"2021","unstructured":"Wander SA, Han HS, Zangardi ML Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience. J. Natl Compr. Canc. Netw. 1\u20138 doi: 10.6004\/jnccn.2020.7662 (2021) (Epub ahead of print).","journal-title":"J. Natl Compr. Canc. Netw."},{"issue":"24","key":"e_1_3_6_78_2","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized Phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky K","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C Randomized Phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41(24), 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"e_1_3_6_79_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the Phase III postMONARCH trial","volume":"43","author":"Kalinsky K","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the Phase III postMONARCH trial. J. Clin. Oncol. 43(9), 1101\u20131112 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"e_1_3_6_80_2","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.esmoop.2025.105803","article-title":"Real-world treatment patterns and effectiveness after disease progression on CDK4\/6 inhibitors for HR-positive\/HER2-negative metastatic breast cancer in the ESME-MBC cohort","volume":"10","author":"Varnier R","year":"2025","unstructured":"Varnier R, P\u00e9rol D, Jacot W Real-world treatment patterns and effectiveness after disease progression on CDK4\/6 inhibitors for HR-positive\/HER2-negative metastatic breast cancer in the ESME-MBC cohort. ESMO Open 10(10), 105803 (2025).","journal-title":"ESMO Open"},{"issue":"7","key":"e_1_3_6_81_2","doi-asserted-by":"crossref","first-page":"105330","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer","volume":"10","author":"Tarantino P","year":"2025","unstructured":"Tarantino P, Lee D, Foldi J Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open 10(7), 105330 (2025).","journal-title":"ESMO Open"},{"issue":"9","key":"e_1_3_6_82_2","first-page":"PS08","article-title":"Abstract PS08-03: sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis","volume":"84","author":"Occhiogrosso Abelman R","year":"2024","unstructured":"Occhiogrosso Abelman R, Spring L, Fell G, Davis A, Hensing W, Ryan P. Abstract PS08-03: sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. Cancer Res. 84(Suppl. 9), PS08\u201303 (2024).","journal-title":"Cancer Res."},{"issue":"4","key":"e_1_3_6_83_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud F","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Br. J. Cancer 131(4), 702\u2013708 (2024).","journal-title":"Br. J. Cancer"},{"key":"e_1_3_6_84_2","unstructured":"RCT-DUPLICATE. https:\/\/www.rct-duplicate.org\/projects.html"},{"issue":"3","key":"e_1_3_6_85_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-023-07145-1","article-title":"Outcomes of male patients with HR+\/HER2\u2013 advanced breast cancer receiving palbociclib in the real-world POLARIS study","volume":"203","author":"Blum JL","year":"2024","unstructured":"Blum JL, Dicristo C, Gordon D Outcomes of male patients with HR+\/HER2\u2013 advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Res. Treat. 203(3), 463\u2013475 (2024).","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"e_1_3_6_86_2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen DK","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J. Clin. Oncol. 41(11), 2087\u20132097 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:52:54Z","timestamp":1779285174000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.57264\/cer-2025-0186"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0186","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"e250186"}}